Back to School: How biopharma can reboot drug development. Access exclusive analysis here
MLNM plans to reduce its headcount by 600 to 1,700 from 2,300 by the end of 2004 in order to focus on
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury